非那雄胺联合α-受体阻滞剂治疗前列腺增生临床疗效观察  

Therapeutic effect of finasteride combined with α-receptor blockers on benign prostatic hyperplasia

作　　者：朱敏 

机构地区：[1]上海市奉城医院药剂科,上海201411

出　　处：《实用临床医药杂志》2012年第9期85-87,共3页Journal of Clinical Medicine in Practice

基　　金：中国高校医学期刊临床专项资金(11220031)

摘　　要：目的探讨非那雄胺联合α-受体阻滞剂对前列腺增生的临床治疗效果。方法根据治疗方法将198例前列腺增生患者分为A组(非那雄胺治疗组,n=70)、B组(α1-受体阻滞剂治疗组,n=62)、C组(联合治疗组,n=66)。观察3组患者治疗24周后的IPSS评分、最大尿流率、B超测残余尿量及前列腺体积。结果 A组与B组治疗后IPSS评分、最大尿流率、残余尿量及前列腺体积均无明显差异(P>0.05);与A组和B组比较,C组治疗后的最大尿流率明显增加(P<0.01),残余尿量及前列腺体积明显减小(P<0.01)。结论联合用药治疗前列腺增生效果显著。Objective To explore the clinical efficacy of finasteride combined withα-receptor blockers for benign prostatic hyperplasia（BPH）.Methods A total of BPH 198 patients were divided into group A（finasteride treatment group,n=70）,group B（α1-blocker treatment group,n=62）,and group C（combined treatment group,n=66）.After 24 weeks of treatment,IPSS score,maximum flow rate,B-mode ultrasound measured residual urine volume and prostate volume in these three groups were observed.Results After treatment,there were no statistically significant differences in groups A and B in terms of IPSS score,maximum flow rate,residual urine volume and prostate volume（P〉0.05）.Compared with groups A and B,the maximum flow rate significantly increased in group C（P〈0.01）.Residual urine volume and prostate volume significantly reduced（P〈0.01）.Conclusion The efficacy of combined drug treatment for BPH is remarkable.

关 键 词：前列腺增生 非那雄胺 Α-受体阻滞剂 

分 类 号：R697.32[医药卫生—泌尿科学]